financetom
Business
financetom
/
Business
/
Travel + Leisure Q2 Adjusted Earnings, Net Revenue Rise; Offers Q3, Full Year Adjusted EBITDA Guidance
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Travel + Leisure Q2 Adjusted Earnings, Net Revenue Rise; Offers Q3, Full Year Adjusted EBITDA Guidance
Jul 24, 2024 4:34 AM

07:02 AM EDT, 07/24/2024 (MT Newswires) -- Travel + Leisure ( TNL ) reported Q2 adjusted earnings Wednesday of $1.52 per diluted share, up from $1.33 a year earlier.

Analysts polled by Capital IQ expected $1.41.

Net revenue for the quarter ended on June 30 was $985 million, up from $949 million a year earlier.

Analysts surveyed by Capital IQ expected $987.2 million.

The company expects Q3 adjusted EBITDA of $235 million to $245 million. Analysts polled by Capital IQ expect $238.7 million. The company updated its full-year adjusted EBITDA to a new range of $915 million to $935 million versus the prior outlook of $910 million to $930 million. Analysts polled by Capital IQ expect $921.6 million.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Ondas Stock Falls Wednesday Despite Strong Revenue, Israel Contract News
Ondas Stock Falls Wednesday Despite Strong Revenue, Israel Contract News
Mar 11, 2026
Ondas Inc ( ONDS ) shares are trading lower Wednesday afternoon, even as investors weigh a string of recent company announcements that highlight strong revenue momentum and expansion in its defense technology business. Here’s what investors need to know. Ondas ( ONDS ) stock is among today’s weakest performers. What’s behind ONDS decline? Ondas Reports Strong Preliminary Revenue, Secures Israel...
Solid Biosciences Reports Interim Phase 1/2 Results in Duchenne Trial
Solid Biosciences Reports Interim Phase 1/2 Results in Duchenne Trial
Mar 11, 2026
02:22 PM EDT, 03/11/2026 (MT Newswires) -- Solid Biosciences ( SLDB ) on Wednesday reported interim results from its phase 1/2 trial of SGT-003, a gene therapy being developed to treat Duchenne muscular dystrophy. So far, 40 participants have received the treatment. The company said the therapy has been generally well tolerated and that interim analyses suggest robust microdystrophin expression,...
Nvidia Launches Nemotron 3 Super AI Model for Agentic Systems
Nvidia Launches Nemotron 3 Super AI Model for Agentic Systems
Mar 11, 2026
01:58 PM EDT, 03/11/2026 (MT Newswires) -- Nvidia ( NVDA ) launched Nemotron 3 Super, a 120-billion-parameter open artificial intelligence model designed to power complex agentic AI systems at scale. The model combines advanced reasoning and high efficiency to help autonomous AI agents complete tasks more accurately while lowering computing costs, supported by a 1-million-token context window that allows agents...
Vicor Insider Sold Shares Worth $8,862,569, According to a Recent SEC Filing
Vicor Insider Sold Shares Worth $8,862,569, According to a Recent SEC Filing
Mar 11, 2026
02:23 PM EDT, 03/11/2026 (MT Newswires) -- Patrizio Vinciarelli, 10% Owner, Director, Chairman and CEO, on March 10, 2026, sold 50,000 shares in Vicor ( VICR ) for $8,862,569. Following the Form 4 filing with the SEC, Vinciarelli has control over a total of 9,629,288 common shares of the company, with 9,458,163 shares held directly and 171,125 controlled indirectly. SEC...
Copyright 2023-2026 - www.financetom.com All Rights Reserved